Cytogenetic abnormalities according to ELN 2022 and survival in patients with NPM1^mutAML. Overall survival (A), event-free survival (B), and cumulative incidence of relapse (C) according to cytogenetic risk as defined in the ELN 2022 genetic risk classification. Patients from the same cohort with NPM1^WT status with adverse-risk cytogenetics served as an adverse-risk comparator. Patients with high FLT3-ITD allelic ratio were excluded. AK, adverse karyotype; CR1, first complete remission; HR, hazard ratio; IK, intermediate abnormal karyotype; NK, normal karyotype.